Artrya (AYA) AGM 2024 summary

Opening remarks and agenda

• Meeting began with a chairman's address, joint presentation, software demonstration, and formal business including voting on resolutions.

• Attendees included both in-person and virtual participants, focusing on company progress and future growth.

Financial performance review

• A successful AUD 5 million capital raise was completed to extend the financial runway and reduce risk.

• Small revenue generated from the first commercial client in Australia, with discounted pricing for early adoption.

• Achieved significant progress in commercialising Salix in Australia and the US, including FDA submissions and registrations.

• Secured strategic partnerships with three US hospital groups, expanding access to 15 hospitals and numerous clinics.

• Received $3.3 million funding under the Medical Research Future Fund for Salix AI analysis of a major CCTA image database.

Board and executive committee updates

• CEO Matt Regan joined in April of the previous year, focusing on FDA engagement and product development.

• Senior-level changes and new hires were made to strengthen regulatory and product teams.

• Board and executive team thanked for their efforts and alignment around 2025 milestones.